Knight Therapeutics Stock Investor Sentiment

KHTRF Stock  USD 3.76  0.06  1.62%   
Roughly 52% of Knight Therapeutics' stockholders are presently thinking to get in. The analysis of overall sentiment of trading Knight Therapeutics pink sheet suggests that some investors are interested at this time. The current market sentiment, together with Knight Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Knight Therapeutics stock news signals to limit their universe of possible portfolio assets.
Knight Therapeutics pink sheet news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Knight daily returns and investor perception about the current price of Knight Therapeutics as well as its diversification or hedging effects on your existing portfolios.
  
over six months ago at news.google.com         
Closing Bell Knight Therapeutics Inc down on Tuesday - Barchart
Google News at Macroaxis
over six months ago at news.google.com         
Closing Bell Knight Therapeutics Inc up on Wednesday - The Globe and Mail
Google News at Macroaxis
over six months ago at news.google.com         
Knight Therapeutics Announces Launch of Bijuva in Canada - Marketscreener.com
Google News at Macroaxis
over six months ago at news.google.com         
Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203 -...
Google News at Macroaxis
over a year ago at news.google.com         
Knight Therapeutics Announces Product Launch for IMVEXXY in Canada - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbre...
Google News at Macroaxis
over a year ago at news.google.com         
Marinus Pharmaceuticals Announces Seven Presentations at AES ... - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Ardelyx Announces Departure of Board Member -November 13 ... - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Knight Therapeutics Reports Third Quarter 2023 Results - Yahoo Finance
Google News at Macroaxis
over a year ago at news.google.com         
Notice of Knight Therapeutics Third Quarter 2023 Results Conference Call - Yahoo Finance
Google News at Macroaxis
over a year ago at news.google.com         
Knight Therapeutics Stock Value Drops 44 percent In Five Years By Investing.com - Investing.com Cana...
Google News at Macroaxis
over a year ago at news.google.com         
Ardelyx Shares Positive Data on Symptom Response During ... - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Ardelyx to Present Data Updates for XPHOZAH for ... - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Carlson Capital L P Adds Glatfelter Corp to Its Portfolio - GuruFocus.com
Google News at Macroaxis
over a year ago at news.google.com         
Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil - Incyte - Benzinga
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Knight Therapeutics that are available to investors today. That information is available publicly through Knight media outlets and privately through word of mouth or via Knight internal channels. However, regardless of the origin, that massive amount of Knight data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Knight Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Knight Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Knight Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Knight Therapeutics alpha.

Knight Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for Knight Pink Sheet analysis

When running Knight Therapeutics' price analysis, check to measure Knight Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Knight Therapeutics is operating at the current time. Most of Knight Therapeutics' value examination focuses on studying past and present price action to predict the probability of Knight Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Knight Therapeutics' price. Additionally, you may evaluate how the addition of Knight Therapeutics to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas